Vehreschild MJGT, et al. - Researchers conducted the ANEMONE study to investigate fidaxomicin treatment for Clostridium difficile infection (CDI) in patients with inflammatory bowel disease, fulminant or life-threatening CDI, severe renal impairment, moderate-to-severe hepatic impairment and pregnancy. Researchers reviewed hospital records from Austria, Germany, Spain and the UK (June 2012–June 2015) to collect data from hospital admission to 30 days after last fidaxomicin dose. In this work, despite the presence of ≥ 1 of the medical conditions of specific interest [inflammatory bowel disease, fulminant or life-threatening CDI, severe renal impairment, moderate-to-severe hepatic impairment and pregnancy] among almost half of fidaxomicin-treated patients, the majority of patients in all subgroups had positive responses to treatment, and no particular safety concerns were identified.